Nosocomial infection, healthcare-associated infection and infection control

The excerpt below, from the MedMarket Diligence whitepaper on “High Growth Medical Technologies“, highlights almost too briefly the challenge and the resulting opportunities associated with addressing the growing demand of infection control:

Infection Control

Numerous frightening scenarios suggesting the world is on the verge of an epidemic that will devastate populations have already been envisaged and have therefore given weight to the alarms sounded on AIDS, Ebola, SARS, bird flu and others. In the not so distant past, even influenza (which we now consider as eminently treatable) was responsible for a devastating epidemic.

It is imperative that healthcare providers recognize and deal with antibiotic resistance and it is therefore equally imperative, since the efficacy of established antibiotics is in an inevitable decline, that alternatives are developed to prevent, contain and treat the host of emerging, virulent pathogens.

The great opportunity in infection control is not limited to a focus on worldwide plague, but to the most common, most problematic and, therefore, most costly type of infection, nosocomial infection.

As we note, nosocomial infection — also known as hospital-acquired infection — is among a number of sources of high cost in not only the U.S. but all healthcare systems globally, others including chronic diseases like obesity and slow-healing wounds.

The medical technology manfuacturer, Kimberly-Clark, reflecting the expanding reach and scope of the problem, has just introduced a website focused on “healthcare-associated infection” (HAI).  The site, http://www.haiwatch.com

While we focus on advanced medical technologies in this blog, we recognize the nature of market opportunity for manufacturers, which sometime emerges very directly from challenges faced by clinicians and healthcare systems. A great many advanced medical technologies have indeed emerged to address needs like healthcare-associated infection, but as clinicians and researchers are facing, the moving target of HAIs has made it clear that significant opportunity still exists.

Leave a Reply